Altogether, these aforementioned in vivo findings demonstrated that the combination therapy of RC48 and dabrafenib significantly inhibits melanoma growth in vivo, providing initial rationale for future clinical evaluations of the anti-HER2 drug conjugate, either alone or in combination with BRAF inhibitor, for the treatment of BRAF mutant cutaneous melanoma. This evidence concerns the gene ERBB2 and cutaneous melanoma.